Whilst fold-changes in fluorescent signal were observed to be modest by imaging with this technique 130 (Fig 4) , negative controls did not increase in fluorescence and specificity of probe cleavage by MMPs 131 and thrombin was confirmed by MALDI-TOF MS analysis. The global enzymatic levels on the surface 132 of the plaque could be limited for a number of reasons. The extent of plaque in each surgical resection 133 was varied, and it would not be expected that the whole of the excised tissue would be highly active in 134 MMP. Additionally, washing of the atherosclerotic plaque in PBS was necessary following surgical 135 extraction, and this would likely have removed enzyme. Despite this, activated dual-probe 3 was 136 detected by imaging and MALDI-TOF MS. 
Probe synthesis. General methods 173
The FRET peptide sequences for MMP and thrombin were individually synthesized by standard Fmoc 174 solid-phase peptide chemistry. Dyes and quenchers were coupled also by standard solid-phase methods.
175
General procedures are as follows: 176
Manual peptide synthesis was performed on Aminomethyl-ChemMatrix™ resin using an Fmoc-Rink 177 amide linker. 178
Coupling of Fmoc-Rink amide linker: The Fmoc-Rink-amide linker (0.54g, 1.0 eq) was dissolved in 179 DMF (10 mL) and Oxyma (0.14g, 1.0 eq.) was added and the mixture was stirred for 10 min.
180
Diisopropylcarbodiimide (DIC, 155 µL, 1.0 eq.) was then added and the solution stirred for 1 min before 181 adding it to Aminomethyl-ChemMatrix resin (1.0 g, 1.0 mmol/g). The resulting mixture was stirred at 182 50⁰C for 45 min and washed with DMF (3x10 mL), DCM (3x10 mL) and MeOH (3x10 mL). Finally 183 the resin was treated with Ac2O:Py:DMF (2:3:15) for 30 min in order to cap any remaining free amino 184 groups and it was washed again with DMF (3x10 mL), DCM (3x10 mL) and MeOH (3x10 mL). Resin 185 loading [6] was measured as ~0.58 mmol/g. 186
Fmoc deprotection:
In general, to the resin pre-swollen in DCM was added 20% piperidine in DMF 187
and shaken (2x10 min). The solution was drained and the resin washed with DMF (3x10 mL), DCM 188 (3x10 mL) and MeOH (3x10 mL). In the cases were Fmoc deprotection was carried out on Cy5 189 containing peptides, a solution of 2% DBU in DMF (2 × 10 min) was used. 190 S11 To the resin pre-swollen in DCM was added 2% hydrazine in DMF and shaken (5x10 min). The solution 202 was drained and the resin washed with DMF (3x10 mL), DCM (3x10 mL) and MeOH (3x10 mL). (b) 203
Selective Dde deprotection [7] in Fmoc-protected peptides was achieved with a solution containing 204
Imidazole ( hexafluorophosphate (HSPyU) (1.0 eq) and DIPEA (3 eq) at 40⁰C for 1h. Once the activation was 211 complete the solution was added to the resin together with DIPEA (3 eq) and shaken overnight. The 212 solution was drained and the resin washed with DMF until colourless wash solution, then DCM (3x5 213 mL) and MeOH (3x5 mL). 214 QSY21 coupling: N-terminal capping with QSY21-NHS ester (1.0 eq per amine) was carried out in 215 anhydrous DMF (0.1M) containing DIPEA (3 eq) for 12 h. The solution was drained and the resin 216 washed with DMF until the wash solution was colourless, then DCM (3x5 mL), MeOH (3x5 mL) and 217 finally ether (3x5 mL). 218
Methyl Red-NHS coupling: Methyl Red-NHS ester (1 eq) coupling on the solid-phase was carried out 219 in anhydrous DMF (0.1M) containing DIPEA (3 eq) for 12 h. The solution was drained and the resin 220 washed with DMF until the wash solution was colourless, DCM (3x5 mL), MeOH (3x5 mL) and finally 221 ether (3x5 mL). 222
Cleavage and purification: The resin, pre-swollen in DCM, was treated with a cleavage cocktail of 223 TFA:triisopropylsilane(TIS):water (95:2.5:2.5) for 3h at room temperature. The reaction solution was 224 drained and the resin washed with the cleavage cocktail. The combined solution was precipitated against 225 cold ether, the peptide collected by centrifugation (x3) and purified by RP-HPLC on a C18 semi-226 preparative column. The desired fractions containing the product were collected and lyophilized to 227 afford the products that were characterized by MALDI TOF MS and analytical HPLC. Thrombin substrates (Scheme S2) were built on the resin, cleaved and purified following the general 236 procedures described above. 237 238 Hydroxysuccinimide (0.59 g, 1 eq) in EtOAc-Dioxane (1:1, 50 mL) was stirred at 0⁰C and DCC (1.0 g, 259 1 eq) was added allowing the mixture to reach room temperature and kept at these conditions for 12 h. 260
The DCU formed was removed by filtration and the filtrate concentrated under vacuum. EtOAc (100 261 mL) was added and washed with 5% NaHCO3 (2x40 mL), water (40 mL) and brine (40 mL). After 262 drying over anhydrous Na2SO4 and concentrating in vacuo the target compound was recrystallized from 263 DCM/Hexane to obtain a white solid that was used in the next step without further purification. in 20% TFA in dichloromethane (10 mL) and the resulting mixture was stirred for 3h. The solvent was 277 removed under vacuum and co-evaporated with toluene. The crude was dissolved in anydrous DMF (5 278 mL). Methyl Red-NHS ester [9] (1.1 g, 1 eq) and DIPEA (1.5 mL, 3eq) were added and the mixture 279 stirred overnight. The solvent was removed under vacuum and the crude mixture dissolved in DCM 280 (150 mL). HCl 1N (100 mL) was added and extracted again with DCM (2x100 mL). The combined 281 organic phases were dried over anhydrous Na2SO4, evaporated under vacuum and purified by silica 282 column chromatography (1:10 to 1:3 MeOH/EtOAc) to afford Methyl Red-Lys- (N-4-pentynoyl) : 1,3,3-trimethyl-2-((1E,3Z,5E)-3-(5-carboxypyridin-2-yl)-5-(1,3,3-292   trimethyl-5-sulfonatoindolin-2-ylidene)penta-1,3-dien-1-yl)-3H-indol-1-ium-5- 
MMP substrates were built on the resin following the general procedure described above. Sulfo-Cy5 309 and QSY21 labelling was carried out as follows: bis(tetramethylene)-O-(N-succinimidyl)uronium hexafluorophosphate (HSPyU) (1 eq) and DIPEA (3 317 eq) at 50⁰C for 1h. Once the activation was complete the solution was added to the resin together with 318 DIPEA (3 eq) and shaken overnight. The solution was drained and the resin washed with DMF until 319 colourless wash solution, DCM (3x5 mL) and MeOH (3x5 mL). N-terminal Fmoc deprotection was 320 carried out using 2% DBU in DMF (2 x 10 min). In the last step to introduce the quencher, N-terminal 321 capping with the QSY21-NHS ester (1 eq) was carried out in anydrous DMF containing DIPEA (3 eq) 322
for 12 h. The solution was drained and the resin washed with DMF until the wash solution was 323 colourless, DCM (3x5 mL), MeOH (3x5 mL) and finally ether (3x5 mL). Cleavage and purification 324 were done according to the general procedure to obtain the following compounds: 325 
Scheme S5. Synthesis of dual-probes exemplified for compound 3 343
General procedure for the fabrication of the dual-probes by Cu-catalysed azide-alkyne cycloaddition 344 chemistry. Optimized conditions for the click reaction were used. [11] In an eppendorf tube the following 345 aqueous reagents were mixed: alkyne-peptide fragment (a, b or c) (50 µL, 1mM), azide-peptide 346 fragment (d, e, f or g) (50 µL, 1mM), premixed CuSO4 and THPTA (40 µL CuSO4 20mM and 80 µL 347 THTPA 50 mM), aminoguanidine hydrochloride (250 µL, 100 mM) and finally sodium ascorbate (250 348 µL, 100 mM). The reaction was allowed to proceed at 30⁰C for 5h, the reaction mixture was lyophilised 349 and purified by HPLC to give the final dual-probes, which were characterized by MALDI and analytical 
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3333.998 3333.765 4.041
3188.840 3188.966 4.471 Buffer (10X) buffer, Thermo Scientific) overnight at 37 °C (with 50 µM Marimastat when 402 appropriate). Gels were stained with Simply Blue Safe Stain (Thermo Scientific) according to 403 manufacturer's instructions. PRP was harvested from whole murine blood as described above for human 404
PRP. 405
Plate reader assays were performed as described in the main text, with the MMP buffer replaced with 406 lavage fluid or PRP. All experiments were carried-out in duplicate. Data was normalised by background 407 subtraction of intrinsic fluorescence. 408
PEPTIDE SEQUENCE OPTIMIZATION OF THE MMP-2/9/13 SUBSTRATE 410
To generate molecular probe sequences to optimally/specifically measure MMP activity the probes 411 were synthesised as shown below: 412 413 414 415 Table S3 . Library of the FRET compounds generated/screened and iterated from the first to fourth 416 generation. The MMP cleavage site is indicated by italics. *Structure of the tail for each generation of 417 probe. 418
419
The initial library of FRET activatable probes (Table S3 -Generation 1 probes) contained the 420 fluorophore 5,6-Carboxyfluorescein and the quencher Methyl Red separated by a peptide sequence 421 acting as the substrate for the target enzyme. Sequence 1 was selected according to a previous proteomic 422 study using iTRAQ-TAILS.
[15] Other sequences were designed and included in the initial G1 screen 423 after analysis of commercial and other reported MMP substrates. 424
The FRET peptides were synthesized by manual standard solid-phase Fmoc chemistry and evaluated as 425 MMP substrates. The response towards MMP and the specific inhibition with the MMP inhibitor 426
Marimastat was measured (Fig S14) , with site specific cleavage confirmed for all the sequences (Table  427 S3) by MALDI-TOF MS analysis. The others MMPs tested shared the same cleavage site. 428
Specific inhibition of fluorescence signal using Marimastat (a pan-MMP inhibitor) was successful for 429 all the probes tested. Control probes (sequence 2 and 6) containing D-aminoacids in the cleavage site 430 showed no increase in fluorescence and no cleavage was detected by MALDI TOF MS. 431
Selectivity was determined by analysis of the change in fluorescence over background upon the addition 432 of different proteases (MMP -2, -9, -12, -13, Neutrophil elastase and Thrombin). In order to choose the 433 best probes for in vivo or ex vivo use a number of additional parameters were evaluated which included 434 fluorescence increase in the presence of other related inflammatory proteases such as Thrombin and 435
human Neutrophil Elastase (NE) (Fig S15 and Table S4 ). 436
437
Results from the generation 1 experiments indicated that sequences 3 and 8 were cleaved by NE, clearly 438 a major issue for a probe for use with tissue. MALDI TOF MS analysis performed after enzymatic 439 treatment confirmed the probes were being cleaved by NE at a different site to those found for the 440
MMPs. NE cleaved probe 3-G1 at -G-P-K-G-I↑K-G-and probe 8-G1 at P-F-G-I↑K-βA (Fig S16-S17 ).
441
The other sequences remained intact and Thrombin did not cleave any of the sequences.
443
The probes containing Methionine in the cleavage site (sequences 5 and 10-16), which were selectively 444 cleaved by MMPs were deprioritised due to the anticipated stability issues that thioether oxidation can 445 cause. Assays with with human tissue homogenate confirmed specific cleavage and inhibition with 446
Marimastat only for sequence 1 (-G-P-K-G↑L-K-G-) and sequence 9 (-P-F-G↑Nle-K-ßA-) (Fig S20-447  S21 ). All these assays were conducted using standard FRET peptides prior to lead optimisation for 448 incorporation into the dual-probes. Table S4 . Relative enzymatic specificity of the Generation 1 compounds (at 10 µM) with 458 excitation/emission at 485/528nm. Recombinant human catalytic domain MMPs -2, -9, -12, -13 were 459 used at 30nM. Neutrophil elastase was used at 30 nM, neutrophil lysate was used neat. Recombinant 460 human Thrombin was used at 5U/ml. Cleavage site for each sequence is indicated in italics. As shown 461 below probe 1 was rapidly cleaved by Plasmin while 9 was observed to be stable to Plasmin. 
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Next Generation Probes: 493
For the next generation probes sequences 1 and 9 were incorporated into peptides that were stabilised 494 with various hydrophilic tails (added in order to improve the aqueous solubility and prevent 495 exopeptidase cleavage. The two selected sequences 1 and 9 were thus flanked by ethylenglycol units 496 (8-amino-3,6-dioxaoctanoic acids) and Lys or D-Lys residues giving the Generation-2, -3 and -4 497 compounds ( Figure S22) . 498
With the second generation of probes, the selectivity for MMPs and Plasmin was evaluated. 499 500 Figure S22 . Structures of compounds in Generation-2, -3 and -4 501 a) MMPs vs Plasmin selectivity: 502
Experiments with MMP-9,-13 and plasmin were carried out in parallel with the selected sequences.
503
Comparison of results provided by compounds 1-G2 and 9-G2 indicated that sequence 1 was cleaved 504 by plasmin while sequence 9 was totally plasmin resistant. MALDI TOF MS analysis ( Figure S23 -S24) 505 was carried out and plasmin cleavage site for sequence 1 was identified as (-G-P-K↑G-L-K-G-).
506
Attempts to make a resistant version replacing the lysine residue with D-aminoacids (-G-P-(D)K-G-L-507 K-G-) resulted in the failure of enzymatic recognition by the MMPs. The combination of PEG units with Lysine increased the aqueous solubility progressively with each 517 generation although the fragment -K-K-(PEG2)2-NH2 used in generation 3 (compounds 1-G3 and 9-518 G3) was unspecifically cleaved when the probes were assayed in tissue homogenate ( Figure S25) . A 519 final iteration with the plasmin resistant sequence 9 (compound 9-G4) was synthesized containing as a 520 hydrophilic tail alternate D-Lys as a non-natural aminoacid and PEG units resulting in good solubility 521 and stability as confirmed by MALDI TOF MS and HPLC analysis. The fluorescence increase was 522 selective for MMPs over plasmin (Fig S26) . Fluorescence signal of compounds 9-G3 and 9-G4 in the presence of different enzymes. 533
534
In summary from these studies the optimized structure for the MMP probe was selected as PFGNleKA 535 attached to the hydrophilic tail -[PEG2-(D)K]3-NH2 and this was used to construct the optimized dual-536 probe. The widley used MMP peptide GPKGLKG was shown to be non-viable due to its cleavage by 537 endogenous enzymes such as Plasmin. Whilst the initial MMP-peptide sequence was chosen for 538 gelatinases MMP-2 and MMP-9 selectivity [15] our final modified peptide sequence was also highly 539 selective for MMP-13, a collagenase which along with MMP-2 and MMP-9 is upregulated within 540 inflammatory microenvironments. [16] It is not wholly surprising that our peptide sequence was activated 541 by these three different MMPs as they share common targets such as gelatin and several collagen sub-542 types.
[17] 
